European Psychiatry - Volume 41 - April 2017

98 / 916

S94 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S69–S105
ferent conditions impact on their overall well being and be active
participants. The tool will be practically demonstrated.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
O070
The efficacy and safety of lurasidone
in adolescent patients with
schizophrenia: Results of functional
and quality of life measures from a
6-week, double-blind,
placebo-controlled study
R. Findling ∗, R. Goldman , J. Cucchiaro , L. Deng , A. Loebel
1 Johns Hopkins University and the Kennedy Krieger Institute,
Department of Psychiatry and Behavioral Sciences, Baltimore, MD,
USA
2 Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, NJ, USA
3 Sunovion Pharmaceuticals Inc., Clinical Operations, Fort Lee, NJ, USA
4 Sunovion Pharmaceuticals Inc., Biostatistics, Fort Lee, NJ, USA
5 Sunovion Pharmaceuticals Inc., Clinical Development, Fort Lee, NJ,
USA
∗ Corresponding author.
Introduction Lurasidone, an atypical antipsychotic, demon-
strated efficacy and safety in adults with schizophrenia.
Objective/Aims To evaluate the efficacy and safety of lurasidone
in adolescent patients with schizophrenia.
Methods Adolescents (13–17 years old) with schizophrenia were
randomly assigned to six weeks of double-blind treatment with
lurasidone 37mg/day, 74mg/day or placebo. An ANCOVA using
an LOCF approach was performed to assess change from baseline
on secondary study endpoints: Pediatric Quality of Life Enjoyment
and Satisfaction Questionnaire (PQ-LES-Q) and Children’s Global
Assessment Scale (CGAS).
Results Patients were randomized to lurasidone 37mg/d
(n = 108), 74mg/day (n = 106), or placebo (n = 112). Placebo-
adjusted LS mean improvement at week 6 on the PQ-LES-Q was
5.3 (P = 0.001) and 5.8 (P < 0.001) for the 37mg/day and 74mg/day
groups, respectively; and, on the CGAS was 4.6 (P= 0.002) and 4.9
(P < 0.001) for the 37mg/day and 74mg/d groups, respectively.
The most common adverse events occurring at ≥ 5% in either
lurasidone group and at least twice the rate of placebo were:
nausea, somnolence, akathisia, vomiting and sedation. Mean
change in weight at week 6 for placebo, 37mg/day, and 74mg/day
groups was 0.05 kg, 0.17 kg, and 0.49 kg, respectively. Lurasidone
treated patients did not show clinically meaningful differences
from placebo on laboratory measures of cholesterol, triglycerides,
glucose, and prolactin.
Conclusions Adolescent patients with schizophrenia treatedwith
lurasidone demonstrated significant improvement in quality of
life and function. Lurasidone was generally well-tolerated and
associated with minimal changes in weight and metabolic parame-
ters. Sponsored by Sunovion Pharmaceuticals Inc. ClinicalTrials.gov
identifier: NCT01911429.
Disclosure of interest Dr. Findling receives or has received
research support, acted as a consultant and/or served on a speaker’s
bureau for Alcobra, American Academy of Child & Adolescent
Psychiatry, American Physician Institute, American Psychiatric
Press, Bracket, CogCubed, Cognition Group, Coronado Biosciences,
Dana Foundation, Elsevier, Forest, Guilford Press, Ironshore, Johns
Hopkins University Press, Jubilant Clinsys, KemPharm, Lundbeck,
Merck, NIH, Neurim, Novartis, Otsuka, Oxford University Press,
Pfizer, Physicians Postgraduate Press, Purdue, Rhodes Pharma-
ceuticals, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals,
Transcept Pharmaceuticals, Tris, Validus, and WebMD. Drs. Gold-
man, Cucchiaro, Deng, and Loebel are employees of Sunovion
Pharmaceuticals Inc.
O071
Clinical characteristics associated
with suicide attempt in patients with
bipolar disorder
M.-E.-M. Vismara ∗ ell’Osso , C. Dobrea , L. Cremaschi ,
G. Benedetta , C. Arici , B. Benatti , L. Oldani , A.-C. Altamura
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Department of Psychiatry-University of Milan, Milan, Italy
∗ Corresponding author.
Introduction Bipolar disorder (BD) is a chronic, highly disabling
condition, associated with a high burden of morbidity and mor-
tality, often secondary to suicidal behaviors. In previous reports,
different variables have been associated with a higher risk of sui-
cidal acts, with variable effect.
Objectives To evaluate which socio-demographic and clinical
variables correlate with suicide attempts in bipolar patients.
Aims To enrich literature data about suicidal behaviour in BD.
Methods A sample of 362 BD patients (DSM IV-TR) was retro-
spectively collected and divided in two subgroups, in relation to
the presence of a previous suicide attempt. Socio-demographic
and clinical variables were compared between attempters and
non-attempters using Correctedmultivariate analysis of covariance
(MANCOVA).
Results A total of 26,2% of analyzed patients attempted sui-
cide in their lifespan, and approximately one third of them
had multiple suicide attempts (i.e. ≥ 2; 31%). Depressive polarity
at index mood episode, higher number of psychiatric hospi-
talizations, comorbidity with alcohol abuse, eating disorders
and psychiatric poly-comorbidity were significantly associated
with suicide attempt. Additionally, treatment with lithium, poly-
pharmacotherapy ( ≥ 4 current drugs) and higher recurrence of
psychosocial rehabilitation were significantly more frequent in
patients who attempted suicide.
Conclusions The present paper reported a correlation with some
specific clinical variables and the lifetime presence of suicide
attempt in patients with BD. Although these retrospective findings
did not address the causality issue, theymay be of clinical relevance
in order to better understand suicidal behavior in BD and to adopt
proper strategies to prevent suicide in higher risk patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
O072
What is the relationship between the
levels of work-stress and burnout?
R. Ptacek ∗, J. Raboch , M. Vnukova , D. Dubacova
1 First Faculty of Medicine–Charles University, Department of
Psychiatry, Prague 2, Czech Republic
2 University of New York in Prague, Psychology, Prague, Czech
Republic
∗ Corresponding author.
Objective Burnout is constantly becoming more exhaustively
researched topic. It is assumed there is strong relationship between
burnout and work-stress. The aim of this study was to investi-
gate the relationship between burnout and work-stress in order
to test the hypothesis that there is an association between these
two variables.
Method The study sample comprised of economically active
Czech population, that was a representative sample. Data was
gained through combination of interviews and questionnaires